Background: Chronic cough is a common reason for medical referral and its prevalence is on the rise. With only one pharmaceutical therapy currently under review for the treatment of refractory chronic ...

A dry cough can have many causes, from allergies to viruses. Home remedies and medications may help provide relief. Drinking plenty of water and avoiding allergens or environmental irritants can ...

Also active in this area is Japanese drugmaker Shionogi, with sivopixant (S-600918) in clinical testing for chronic cough and neuropathic pain. Bayer's move leaves Merck still out in front ...

In Merck's COUGH-1 and COUGH-2 trials ... overactive bladder and neuropathic pain, and Bayer is also running phase 2 trials of eliapixant in all these indications. The P2X3 receptor antagonist ...

Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...